Why the study?
Does the use of angiotensin system inhibitors improve survival and manage hypertension in patients with metastatic renal cell carcinoma receiving anti-VEGF therapies?
Does the use of angiotensin system inhibitors improve survival and manage hypertension in patients with metastatic renal cell carcinoma receiving anti-VEGF therapies?
Angiotensin system inhibitors may offer survival benefits and help manage hypertension in patients with metastatic renal cell carcinoma undergoing anti-VEGF therapy.
Answers are grounded in this paper and cite their sources.
May support adjunctive angiotensin system inhibitors for survival in mRCC on VEGF therapy; leaves open need for randomized confirmation.
Arterial hypertension (HTN) is a class effect of anti-vascular endothelial growth factor (VEGF) therapies, including the monoclonal antibody bevacizumab. Data are conflicting regarding the role of the renin-angiotensin system on angiogenesis and recent data suggest that the use of angiotensin system inhibitors (ASIs; angiotensin receptor blockers or angiotensin-converting enzyme inhibitors) is associated with improved survival in metastatic renal cell carcinoma (mRCC), particularly when used with VEGF targeted therapies. The aim of this review is to discuss the available treatment options for mRCC and associated incidence of hypertension as well as summarize the known data about ASIs use and mRCC. Additionally, given that the optimal management of HTN remains unclear, we will focus on prevention strategies and propose potential therapeutic approaches.
No takes yet. Share an insight, caveat, or question.
Derosa et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: